The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent 
| INTRODUCTION
In the past two decades, there has been a major advancement in understanding the functions of the immune system, and one of the foremost achievements is the development of new immune checkpoint inhibitors.
Checkpoint molecules are now sufficiently numerous such that they can be divided into families. The B7-CD28 family can be phylogenetically divided into three groups 1, 2 -Group I consisting of B7-1/B7-2/CD28/ CTLA4 and B7h/ICOS; group II containing PD-L1/PD-L2/PD-1; group III including B7-H3 (CD276), B7x (B7-H4/B7S1), and HHLA2 (B7H7/ B7-H5)/TMIGD2 (IGPR-1/CD28H). The B7-1/B7-2/CD28/CTLA-4 pathway is important in modulating central immune tolerance while PD-L1/PD-L2/PD-1, B7-H3, B7x, and HHLA2 are important in peripheral immune regulation. The discovery, understanding, and therapeutic manipulation of the CTLA4 and PD-1/PD-L1 pathways have led to important therapeutic advances in cancer immunotherapy in patients and have led to improved patient cures and survival. 3, 4 In this review, we will focus on the advances of the new immune checkpoints in the third group of the B7 family namely B7-H3, B7x, HHLA2, and TMIGD2.
| B7-H3
B7 homolog 3 protein (B7-H3) also known as CD276 is an immune checkpoint molecule that belongs to the B7-CD28 family and was DOI: 10.1111/imr.12521
I N V I T E D R E V I E W
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ectodomain, and elucidation of the detailed biophysical properties of the molecule, provides the models for mapping the possible receptorbinding sites and functional analysis.
11
The crystal structure of mB7-H3 construct, including both IgV and
IgC domains, was determined to the resolution of 3 Å with the space group P6 1 22. The ectodomain of mB7-H3 was produced by Drosophila S2 cells and purified as a glycosylated monomer. However, mB7-H3
crystallized as an unusual dimeric form, resulting from the mutual swap of the IgV domain G strands between two adjacent molecules ( Figure 1 ).
The connection segment of the F and G strands adopts an extended "beta strand-like" conformation rather than the classical FG loop conformation of the IgV domains. Consequently, the crystal structure of the mB7-H3 IgV domain is formed by a "back sheet" (ABED strands) and a "front sheet" (C″C′CFG* strands), of which the G* strand is contributed by the neighboring mB7-H3 IgV domain. The mB7-H3 C-terminal
IgC domain (residues 140-239) located on the C terminus of the ectodomain adopts the classical IgC folding with sheets ABED and CFG.
12
Upon days of storage at high concentration at 4°C, monomeric mB7-H3 gradually forms a stable dimer in a concentration-dependent manner. 11 Consistent with the crystal structure of mB7-H3, of which the IgV FG loop residues adopt an unusual extended strand-like conformation, replacements f the residues by other residues in the FG loop perturb the dimerization, suggesting that the observed G loops exchanging in the crystal structure contributes to the dimerization of mB7-H3 in solution. Interestingly, both monomeric and dimeric mB7-H3 showed consistent abilities to inhibit T-cell proliferation with no significant difference. Thus, dimerization of mB7-H3 alone does not change the inhibitory function of the molecule.
11
A canonical monomeric model of mB7-H3 was generated based on the crystal structure of the dimeric mB7-H3. 13 Two potential N-glycosylation sites (residues Asn91 and Asn104) are predicted on the IgV domain of mB7-H3 based on the sequence of the molecule.
Significant electron density was observed near Asn91 and was identified as a single N-acetyl glucosamine (NAG). More electro-density
was observed adjacent to residue Asn104 and was interpreted as two NAG and two mannose sugar residues. Both glycosylation residues and sugars are located in the "back sheet" of mB7H3 IgV domain ( Figure 1 ). A chimera mB7-H3 mutant, of which the whole FG loop F I G U R E 1 Structures of B7-H3, B7x, and PD-L1. A, Overall structure of the dimeric mB7H3 in the crystal (PDB entry 4I0K). The strands from each monomeric mB7H3 are colored and labeled differently. B, The generated model of monomeric mB7H3 based on the crystal structure from PDB entry 4I0K. C, The structure of the hB7x IgV domain (PDB entry 4GOS). D, Superimposition of the monomeric mB7H3, hB7x, and hPD-L1 (PD-L1 is from A chain of the PDB entry 3BIK). The disulfide bonds, carbohydrates, and the connecting Asn residues are shown as sticks (residues 126-129; sequences: IQDF) was replaced to the cognate sequences from human PD-L1 (sequences: YGGA), completely lost the mB7-H3-mediated inhibitory activity. Surprisingly, alanine scanning targeted the residues on the "front sheet" of mB7-H3 IgV domain did not significantly change the inhibitory activity of mB7H3 as compared to the wildtype (WT) mB7H3. 11 These results indicate the individual mutation of the residues on the "front sheet" to alanine may not be sufficient to disrupt the receptor recognition, whereas replacement of the FG loop residues is significant enough to disrupt mB7-H3 function. This also demonstrates that the FG loop is important for mB7-H3-mediated inhibition. 
| Expression

| Function
Our appreciation of the roles of B7-H3 is evolving and the context of its expression is central to further defining the importance of this molecule. Its significance in innate and adaptive immunity is complex and still needs further elucidation.
| Tcell
B7-H3 has been shown to have co-stimulatory and co-inhibitory activities in various studies. The initial study which led to the discovery of B7-H3 showed that B7-H3 increased proliferation of CD4 and CD8 T cells in the presence of anti-CD3 antibody. Moreover, B7-H3
played an important role in the generation of IFN-γ during activation of T cells. 5 In murine cancer models, B7-H3 has been shown to activate tumor-specific cytotoxic T lymphocytes (CTL) and hence potentiate antitumor immunity. 22 These studies showed that mB7-H3 can function as a co-stimulatory molecule.
Several studies show that B7-H3 predominantly causes T-cell co-inhibition. Similar T-cell proliferation assays showed that B7-H3 inhibited proliferation of CD4 and CD8 T cell in a dose-dependent manner and also reduced IL-2 and IFN-γ. 17 This inhibitory effect These studies comprehensively show that B7-H3 causes T-cell coinhibition. These effects of T-cell co-stimulation or co-inhibition by the same molecule could be due to multiple receptors, the presence of other co-stimulatory or co-inhibitory molecules, or the presence of different immune cells/cytokines leading to modulation of B7-H3 function.
| NKcell
B7-H3 has been shown to inhibit NK cell activity in tissue cultures and hence decreases NK cell function and therefore there should be a receptor on NK cells for B7-H3. 23 In glioma, higher grades are associated with a higher percentage of B7-H3 expression. 24 This study also showed that both soluble B7-H3 and cell-bound B7-H3 were able to inhibit NK cell-mediated lysis. In an in vivo model of B7-H3-silenced glioma cell lines, tumor formation was present but there was a marked decrease in the ability to form metastatic deposits when compared with control animals. This is important in tumor immunity, since when tumor cells lose HLA class I molecules, and hence escape cytolytic T-cell clearance, they become susceptible to NK cell-mediated lysis ( Figure 2 ). 
| B7-H3inpathologicalstates
| Infection
Soluble B7-H3 is elevated in patients with sepsis when compared with healthy persons and is even higher in patients who died from sepsis.
26
Whether soluble B7H3 represents a predictive or prognostic factor for sepsis is unclear as this was a small study and other confounding factors could have influenced the reported results. In patients with sepsis, serum B7-H3 levels correlate with increased levels of tumor necrosis factor α (TNF-α) and IL-6. TNF-α is the most potent inducer of B7-H3 release from monocytes. B7-H3 alone was unable to cause cytokine release from murine macrophages but it strongly augmented LPS-induced NF-κβ activation in a Toll-like receptor (TLR) 2-and TLR4-dependent manner. 26 Similarly, B7-H3 substantially augmented pro-inflammatory cytokine production in the development of pneumococcal meningitis in a murine model. 27 Thus, B7-H3 potentiates the inflammatory response in sepsis in murine models. Its levels are higher in humans during sepsis but its significance remains uncertain.
| Transplant
Allogeneic bone marrow transplant (BMT) is performed for hematological malignancies and achieves a cure; however, graft-vs-host disease (GVHD) after allogeneic transplant remains a major cause of death in transplant recipients. B7-H3 is upregulated in the colon, liver, and lung in mice, and in the intestine of GVHD patients. B7-H3 knockout recipients as well as recipients of B7-H3 knockout donor T cells had accelerated GVHD lethality. The increased GVHD lethality is a result of increased T-cell proliferation, colon inflammatory cytokines, and intestinal permeability. However, these T cells lacking B7-H3 are capable of providing graft-vs-leukemia (GVL) effects that are advantageous. Therefore, the B7-H3 pathway acts as a suppressor of acute GVHD. Approaches to increase B7-H3 expression soon after BMT to reduce GVHD and to decrease B7-H3 later post-BMT via the development of potent antagonistic B7-H3 monoclonal antibodies (mAbs)
to enhance the donor lymphocyte infusion-mediated GVL effect may benefit transplant recipients.
28
In solid organ transplants an early study showed B7-H3 had a co-stimulatory role in the alloimmune response. Its expression by cells promotes T cell-mediated immune responses and subsequently mediates the rejection of acute and chronic cardiac and islet cell allografts. 29 However, more recent results are consistent with an inhibitory function of B7-H3. Its signaling prolongs the survival of a fully MHC-mismatched cardiac model and promotes a shift toward a Th2 milieu. 30 Further studies are needed to clarify its role in solid organ transplants.
| Cancer
Aberrant expression of B7-H3 in various human malignancies including melanoma, glioma, leukemia, lung, pancreatic, renal, colorectal, ovarian, breast, gastric, and endometrial cancers was detected in 60-93% of the tumor tissue, while limited expression is seen on normal healthy tissues.
B7-H3 staining by immunohistochemistry (IHC)
is present on the membrane, cytoplasm, nucleus, or vasculature of tumors. A study of more than 700 colorectal cancer patients showed cytoplasmic/membrane, stromal, and nuclear expression of B7-H3
in 86%, 77%, and 27% of the samples, respectively. 31 The molecular mechanisms that regulate its expression and specific functions remain unclear with both favorable and adverse outcomes associated with its expression in human tissues and mouse models. expressed B7-H3, respectively. In both these studies, high levels of B7-H3 expression were associated with a significantly better prognosis. 53, 54 Its expression was correlated with a higher number of tumor-infiltrating CD8 T cells in the pancreatic cancer patients, while in breast cancer B7-H3 suppressed tumor growth by inhibiting VEGF expression. 55 B7-H3 slowed tumor growth mediated by CD8 T cells and 50% had complete regression in mouse models of lymphoma and mastocytoma. 56, 57 In HCC mouse models multiple distant tumor nodules regressed and tumor angiogenesis was inhibited. 58, 59 In colon cancer survival time was prolonged, and tumor size as well as the occurrence of metastases was reduced. 60, 61 Ablation of B7-H3 resulted in increased tumor burden in a spontaneous prostate cancer model. 62 These studies show that a high level of B7-H3 may be beneficial to anti-tumor immune responses.
There are several potential explanations for B7-H3's complex and conflicting immunomodulatory activity: (1) B7-H3 interacts with both inhibitory and stimulatory receptors; (2) it has different affinities for several receptors; (3) it has other aberrant isoforms or splice variants;
and (4) genetic polymorphisms or differential glycosylation patterns may exist for the B7-H3 gene and protein. survival. 67 Currently, Phase I clinical trials with radiolabeled 8H9 are ongoing in patients with peritoneal cancers, gliomas, and advanced
CNS cancers (NCT01099644, NCT01502917, and NCT00089245).
Recently a humanized affinity-matured potent form of this antibody (hu8H9) has been developed that binds to the FG loop of B7-H3, a region critical to its immunologic function.
68
Synergistic therapy with a B7-H3 mAb and chemotherapy has met with preclinical success. In a murine pancreatic cancer model, B7-H3
blockade with the mAb MJ18 along with gemcitabine showed a synergistic anti-tumor effect without overt toxicity. 69 Two other preclinical animal studies have shown that silencing B7-H3 as well as utilizing conventional chemotherapy with cytarabine or paclitaxel led to 80% tumor reduction in murine models of histiocytic lymphoma-derived human cell line U937 and human breast cancer line, respectively, compared to WT models. 52, 70 In both studies, silencing B7-H3 significantly enhanced tumor cell chemosensititvity and drug-induced apoptosis.
Hence, this provides a rationale for the potential synergistic effects between B7-H3 blockade and chemotherapy for treatment of cancers.
The 
| SummaryofB7-H3
B7-H3 is predominantly a T-cell co-inhibitory molecule with a partial co-stimulatory function reported in some studies. It is a type I trans- 
| B7x
B7x (B7-H4, B7-S1) belongs to the Immunoglobulin superfamily and the B7 family of ligands. It was discovered by us and others using bioinformatic analyses in search for proteins with homology to other members of the B7 family. 1, 71, 72 The human B7x (hB7x) consists of 282 amino acids and shares an 87% amino acid identity with mouse B7x which shows that this molecule is conserved from an evolutionary standpoint. It shares varying degrees of identity with human-B7-1 (12%), B7-2 (13%), B7 h (16%), PD-L1 (18%), PD-L2 (18%), and B7-H3 (24%). 1 Human B7x is located on chromosome 1p12/13.1. This is a type 1 transmembrane protein with a signal peptide in the N terminus, an extracellular domain with IgV-and IgC-like domains with four conserved cysteine residues and seven sites for N-linked glycosylation.
| StructureofB7x
The crystal structure of the hB7x IgV domain was determined to the resolution of 1.59 Å with the space group P4 3 2 1 2. The hB7x IgV domain was expressed by Drosophila S2 cells and the purified protein crystallized as a monomeric form with each asymmetric unit containing one hB7x molecule. 73 The structure of hB7x IgV adopts a typical IgV organization, 12 which is characterized by "β sandwich"
folding formed by a "back sheet" (ABED strands) and a "front sheet"
(C"C'CFGA' strands) stabilized by a disulfide bond between B and F strand (formed by Cys56 and Cys130). A significant electron density, which could be fitted by five sugar residues of a branched glycan, is well defined near Asn112, corresponding to the glycosylation site at Asn112 as predicted by hB7x sequences. Notably, the large observed branched glycan covers a significant area of the "back sheet" surface ( Figure 1) . Similarly, a glycosylation site at the homologue position (Asn104 of B7H3) has been observed for the mB7H3 ectodomain.
11
Crystal structure of hB7x provides a model for epitope mapping, which may further improve the efficacy of antibodies targeting hB7x.
For example, 1H3 is an IgG1 mAb against B7x, which has been proved to inhibit tumor nodule formation and prolong the survival of mice inoculated with hB7x-expressing CT26 tumors. 74 The Fab of 1H3 is effective in blocking the B7x-mediated T-cell co-inhibition, suggesting
1H3 is a functional neutralizing antibody. Mutagenesis study showed that BC loop (residues Ile62 and Lys63) of the "back sheet" and FG loop (residue Ser135) of the "front sheet" define the minimal footprint for hB7x:1H3 interaction interface. 73 In combination of these data, it is very likely that the B7x receptor binds to the B7x IgV domain, which overlaps with the 1H3-binding interface. 
75-79
Considering the obvious carbohydrates modifications of both B7-H3
and B7x on the "back sheet" of the IgV domains as identified in the crystal structures, it is very likely that B7-H3 and B7x may interact with their receptors through the "front sheet" of IgV domains, although more concrete evidence is required to support this hypothesis.
| Expression
B7x mRNA in immune cells is expressed by professional APC, bone marrow-derived DCs, peritoneal macrophages, splenic CD11c+ DCs, and splenic B cells. 1, 80 B7x mRNA can be detected by PCR in most tissues but it is highly expressed in non-lymphoid organs like the lung, testis, and pancreas 1 ( Table 1) . Despite the high level of mRNA expression in most tissues, there is no detectable B7x protein in most healthy tissues. 80 Low levels of B7x expression were found in genital tract, lung, pancreas, and kidney, but were absent in other normal somatic tissues.
81
The functional mechanisms of upregulation of B7x in glioma cells were explored. 82 
| Function
| Tcells
B7x negatively regulates T-cell responses. B7x decreases T-cell proliferation, which is a hallmark of T-cell activation, in a dose-dependent fashion by decreasing IL-2 72 and by inducing cell cycle arrest in T cells (a non-IL-2-dependent mechanism). 80 This is similar to CTLA-4 which can also inhibit TCR-induced T-cell proliferation by cell cycle arrest.
83
JunB which regulates IL-2 gene transcription after T-cell activation is decreased after B7x stimulation and this could be one mechanism of decreasing IL-2 production by B7x.
B7x inhibits T-cell growth,
cytokine secretion, and cytolytic activity against allogeneic antigens in vivo. 80 The inhibitory effects of B7x could only be partially reversed by co-stimulation through the CD28 signaling pathway. B7x blocks the differentiation of naïve CD4 T cells to effector Th1 or Th17 cells by blocking IFN-γ and IL-17 production 84 ( Figure 2 ). In all these studies it has been shown that B7x interacts with a receptor on activated T cells which is distinct form CD28, CTLA-4, ICOS, and PD-1. 
| Myeloid-derivedsuppressorcells
Myeloid-derived suppressor cells (MDSCs) are immature cells of the myeloid origin, which are mainly present in tumor and have a potent ability to suppress T-cell proliferation and cytokine production.
85
MDSC are divided into granulocytic (g-MDSC) and monocytic MDSC. 
| B7xinpathologicalstates
| Autoimmunediseasesandinfection
B7x has been shown to dampen T-cell responses. To demonstrate the role of B7x in infections, the effects of Streptococcus pneumonia infection in B7x knockout mice were studied. 87 In the B7x knockout mouse model, the severity of S. pneumonia infection was markedly reduced when compared to WT mice. Control of infection in B7x knockout mice was associated with a marked increase in activated CD4 and CD8 T cells and fewer neutrophils in lungs, whereas the susceptible WT mice had higher neutrophils with decreased CD4
and CD8 T cells. This suggests that B7x plays an important role in the dampening of immune responses to infection. to an inflammatory M1 phenotype. In accord with these studies, high levels of serum B7x were found in the sera of patients with rheumatoid arthritis and correlated with the disease severity score. 91 All these studies show that B7x regulates the induction and severity of autoimmune diseases and plays an important role in peripheral tolerance.
| Cancer
Aberrant expression of B7x has been detected in many human cancers which include-breast, lung, ovary, uterus, kidney, and others. 92 B7x
is rapidly lost in in vitro cultures and hence most human 93 and mouse tumor cell lines are B7x negative. 73 Several human studies have studied the expression of B7x in cancers and its prognostic role in these malignancies. A few studies are described in detail below.
| Prostatecancer
Expression of B7x and correlation with clinical features were analyzed in a large study of 948 patients with localized prostate cancer treated with a pelvic lymph node dissection and radical retropubic prostatectomy. 40 B7x was highly expressed in the majority of prostate cancer with a strong intensity in 15% of cancer specimens. Strong intensity of staining for B7x in tumors was significantly associated with extracapsular extension, seminal vesicle invasion, and metastatic disease.
These patients were also more likely to develop a biochemical recur- is highly expressed in prostate cancer and its strong expression in the tumor is associated with poor prognostic factors.
| Breastcancer
Similar to prostate cancer, B7x expression was detected in 95%-97%
of primary and metastatic breast cancers. The staining intensity was much higher in invasive ductal carcinoma than in normal breast epithelium. 81 Even though B7x expression was associated with negative progesterone receptor status and history of neoadjuvant chemotherapy these factors are not necessarily predictive of a poor outcome in breast cancer.
| Renalcancer
In 259 RCC patients treated with nephrectomy, 59% tumor specimens exhibited B7-H4 staining. 94 RCC patients (14.4 ng/mL) when compared to 18 control patients (2.7 ng/mL). 95 Median levels were significantly higher for patients with a tumor thrombus, positive lymph nodes, and distant metastases at nephrectomy. The median B7x levels also were progressively higher with increasing tumor-node-metastasis stage. These findings suggest that B7x is highly expressed in RCC, is associated with poor prognostic features, and since it is expressed in the vascular endothelium, whether this is involved in angiogenesis or metastases needs to be determined.
| Glioma
In glioma, a CNS tumor, higher grades of tumor are associated with higher B7x mRNA and protein expression when compared with normal brain tissue. 82 Similarly, increasing levels of soluble B7x was also found Based on these studies, B7x is expressed in most cancers and its expression is associated with a poor prognosis. Targeting B7x in human cancers is an attractive option for cancer immunotherapy.
| ImmunotherapytargetingB7x
| Cancer
Anti-B7x therapy has been tested in mouse models in the form of anti-B7x single-chain fragment variables (scFv), ADCC and functional antibodies, antibody drug conjugates, and chimeric antigen receptor (CAR) T cell-B7x therapy. An anti-B7x antibody was generated to study the effects of inhibiting B7x in mouse cancer models. This antibody functions both as a blocking antibody to inhibit function and kill through an ADCC mechanism, and since B7x is evolutionally conserved, the antibody also inhibits hB7x. A colon carcinoma CT26
cell line which stably expressed B7x and induced experimental lung metastasis was tested with anti-B7x treatment. 73 The average number of metastasis was higher along with a poor survival in the B7x/ 
| Autoimmunedisease
In contrast to cancers where inhibition of B7x is beneficial, potentiation of B7x-induced immune suppression has been shown to suppress autoimmune diseases. A non-obese diabetic (NOD) mouse model was used to study the effects of B7x in development of type 1 diabetes. 97 NOD mice were injected with B7x immunoglobulin fusion protein (B7x-Ig) at 3 weeks, before the onset of diabetes.
Early treatment of NOD mice with B7x-Ig resulted in a later development of diabetes. It did not prevent the onset of inflammation but rather decreased the amount of islet cell destruction by modulating the immune infiltrate. This is due to a decreased Th1 response mediated by upregulation of T regulatory cells in the pancreas while this did not happen systemically in the blood. In addition, B7x-Ig-treated mice had decreased numbers of Th17 cells and hence decreased levels of Th17-associated cytokine and an increase in IFN-γ which potently inhibits Th17 cells. 98 The treatment downregulates the Th17 pathway which is important in the development of autoimmune diseases.
99
A similar approach was used to demonstrate that B7x-Ig effectively ameliorated EAE in mice by decreasing CD4 T cells and by increasing the number and function of T regulatory cells. 84 Specifically it blocked IFN-γ and IL-17 production and hence blocks differentiation of naive CD4 T cells to either a Th1 or Th17 phenotype. This could be used as therapeutic model to potentiate the B7x pathway for human demyelinating disorders like multiple sclerosis.
As previously described, a mouse nephritis model was used to demonstrate that B7x decreases autoimmune kidney injury. 90 Following nephrotoxic kidney injury, B7x-Ig inhibits the expansion of CD4 and CD8 T cells and restricts macrophage polarization to a M1
phenotype. The M1 phenotype is likely to cause autoimmune diseases in experimental models. B7x-Ig treatment also decreases the levels of various cytokines involved in autoimmune nephritis namely-CXCL13, IRF5, ICOS-L, and TGF-β. All these studies show that therapeutic potentiation of B7x pathway in humans with preexisting autoimmune diseases or in those with a high risk of developing autoimmune disease is likely to be beneficial.
| SummaryofB7x
B7x is a T cell co-inhibitory molecule with a 15%-25% homology 
| HHLA2
We and others recently identified HHLA2 as a new member of the B7 
| Evolution
HHLA2 is an acronym for Human Endogenous retro virus-H Long
terminal repeat-associating 2. This gene was discovered when a systematic search for human retroviral long terminal repeats (LTR) was performed as these LTR's can possess enhancer, promoter, or polyadenylation functions and one such gene identified was HHLA2.
102
The LTR provides the primary polyadenylation signal and hence this integration is important for this gene to be read and translated to mRNA. The LTR of the HHLA2 locus has been integrated into the primate lineage since it is found only in gorilla, chimpanzee, and humans of the New World. HHLA2 is not expressed in mice but it is expressed in higher primates. The integration of the LTR sequence in higher primates could account for the significant differences in gene expression between the different species.
| Expression
Human Endogenous retro virus-H Long terminal repeat-associating 2 is constitutively expressed on human monocytes and induced on B cells after stimulation with IFN-γ 2 (Table 1) . Most normal tissues do not express HHLA2 except the placenta, intestines, kidney, gallbladder, and breast. 103 The placenta is a site of immune privilege and other co-inhibitory molecules namely PD-L1, B7-H3, and B7-x are also highly expressed by this organ.
| Function
Since HHLA2 belongs to the B7 family, it is hypothesized that HHLA2
regulates T-cell function. HHLA2 immunoglobulin fusion protein . Overall these studies demonstrate that HHLA2 predominantly functions as a T-cell co-inhibitory molecule.
| HHLA2inhumancancers
Human Endogenous retro virus-H Long terminal repeat-associating 2 is expressed in a majority of tumor specimens of the breast, lung, thyroid, melanoma, ovary, and pancreas. 103 The localization of the protein is both membranous and cytoplasmic in tumor cells. Even though HHLA2 is a transmembrane protein, this type of distribution is not uncommon as this could be due to structural differences in staining vs shuttling of the protein between the cytoplasm and the membrane.
HHLA2 protein is also expressed in a lower percentage of other cancers such as liver, bladder, colon, prostate, kidney, and esophagus.
103
The prognostic significance of such an expression was determined in three cancers-breast, osteosarcoma, and lung.
| Breastcancer
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer when compared to estrogen receptor-positive and Her2-positive breast cancer. In a retrospective study, 50 patients with local or locally advanced breast cancer were identified and their clinical characteristics collected. All these patients underwent surgery as the primary treatment followed by chemotherapy or radiotherapy or both. TNBC with a high expression of HHLA2 was associated with lymph node positivity and higher stage at the time of diagnosis, indicating more aggressive disease when compared with tumors with low expression of HHLA2. By analyzing the cBio portal to assess for HHLA2 gene alterations, we found that HHLA2 was altered in 32% of the basal subtype and the vast majority of HHLA2 copy number variations in basal breast cancers were amplifications or gains (>95%). This suggests that one mechanism of upregulation of HHLA2 protein in human cancers could be copy number gain. 
| Lungcancer
| Osteosarcoma
Osteosarcoma is another primary malignancy of the bone with a less than 20% 5-year survival rate and the prognostic role of HHLA2
was recently evaluated. 108 In this study, HHLA2 was expressed in metastatic disease more than in primary disease and the differences was statistically significant (93% vs 53%, P=.02). Higher levels of HHLA2 expression in the tumor (25% vs 50%) portended a worse OS.
Together these studies suggest that HHLA2, by functioning as a T cell co-inhibitory molecule in the tumor microenvironment, could provide a survival advantage for the tumor and hence its expression is associated with a worse prognosis.
| SummaryofHHLA2
Human endogenous retro virus-H Long terminal repeat-associating 2 is a newly discovered T cell immune checkpoint molecule that belongs to the B7 family of ligands. It predominantly functions to inhibit T-cell proliferation and T-cell cytokine responses. HHLA2 is expressed on few normal tissues but it is expressed in various human cancers. High expression of HHLA2 in human cancer of lung, breast, and osteosarcoma is associated with worse prognostic features.
| TMIGD2
We and others recently discovered TMIGD2 (transmembrane and immunoglobulin domain containing 2) as one of the receptors for HHLA2 which is a 31-kDa protein and is present on chromosome 19q13.3. 100, 103 Sequence analysis showed that TMIGD2, the immunoglobulin-containing and proline-rich receptor-1 (IGPR-1), and CD28 homolog (CD28H) are the same molecule. TMIGD2 (IGPR) was originally identified as an adhesion molecule involved in angiogenesis.
Transmembrane and immunoglobulin domain containing 2 is an
Ig superfamily member with an extracellular IgV-like domain, a transmembrane region, and a cytoplasmic tail. The extracellular region has two possible glycosylation sites while the cytoplasmic tail contains tyrosine residues and a proline-rich domain. It shares greater than 10% amino acid identity with other B7 family receptors namely -CD28, CTLA, ICOS, and PD-1. 100 Similar to HHLA2, TMIGD2 is absent in mouse and rat while it is found in higher primates.
109
TMIGD2 is a membranous glycoprotein which is confirmed by immunofluorescence microscopy. TMIGD2 appears to be in a glycosylated form in the thymus, placenta, heart, small intestine, skin, and kidney with a molecular weight of 55 kDa while in the skeletal muscle, brain, colon, lung, and ovary TMIGD2 seems to be unglycosylated with an apparent molecular weight of 35 kDa. 
| CONCLUSIONS
The B7-CD28 family of ligands and receptors play very important roles 
